Michael Freeman
Stock Analyst at Raymond James
(2.93)
# 1,416
Out of 5,147 analysts
5
Total ratings
80%
Success rate
45.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $13.93 | +0.50% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $23.45 | +224.09% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $15.62 | +136.88% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $66.62 | +33.59% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $5.93 | +34.91% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $13.93
Upside: +0.50%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $23.45
Upside: +224.09%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $15.62
Upside: +136.88%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $66.62
Upside: +33.59%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.93
Upside: +34.91%